Global Synovial Sarcoma Treatment Market, By Diagnosis (Imaging, Biopsy, Others), Type (ACXT-3102, AL-3818, Axitinib, CMB-305, CUE-102, Others), Treatment (Surgery, Anti-Angiogenesis, Drugs Radiation Therapy, Chemotherapy), End-Users (Hospitals, Specialty Clinics, Oncology Centers, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others) – Industry Trends and Forecast to 2030.
Synovial Sarcoma Treatment Market Analysis and Size
Synovial sarcoma is a relatively uncommon cancer that is classified as a soft tissue sarcoma (STS) with uncertain differentiation. It is responsible for 5-10% of all STS. The age-adjusted incidence in children is 0.81/1,000,000 and 1.42/1,000,000 in adults, with approximately 1000 patients diagnosed with synovial sarcoma each year in the United States. Synovial sarcoma differs from other STS in that it appears at a younger mean age of onset, is more common in adolescents and young adults (mean age at diagnosis of 39 years), and affects both sexes equally. Synovial sarcoma is the most common non-rhabdomyosarcoma STS in children, accounting for 30% of all STS diagnoses.
Data Bridge Market Research analyses that the synovial sarcoma treatment market which was USD 38.5 billion in 2022, is expected to reach USD 56.88 billion by 2030, at a CAGR of 5% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Synovial Sarcoma Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Diagnosis (Imaging, Biopsy, Others), Type (ACXT-3102, AL-3818, Axitinib, CMB-305, CUE-102, Others), Treatment (Surgery, Anti-Angiogenesis, Drugs Radiation Therapy, Chemotherapy), End-Users (Hospitals, Specialty Clinics, Oncology Centers, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd (Switzerland), Bayer AG (Germany), Epizyme (U.S.), Cue Biopharma (U.S.), Eli Lilly and Company (U.S.), Adaptimmune Therapeutics Plc (U.K.), Advenchen Laboratories LLC (U.S.), EpiZyme Inc (U.S.), Merck & Co., Inc (U.S.), Immunocore Ltd (U.K.), Johnson & Johnson Private Limited (U.S.), Karyopharm Therapeutics Inc (U.S.), Novartis AG (Switzerland), Pfizer Inc. (U.S.) and Takara Bio Inc (Japan)
|
|
Market Opportunities
|
|
Market Definition
Synovial Sarcoma is a rare type of cancer that develops near large joints, particularly the knee. This disease is most likely to affect people between the ages of 15 and 40. Synovial sarcoma is a type of cancer that grows slowly and is more common in men. It is also known as malignant myeloma. The most common symptoms of synovial sarcoma are swelling near the affected areas, which is often painless, and problems using both legs and hands. Synovial sarcoma is characterised by abnormal soft-tissue growth. Synovial sarcoma is highly metastatic and spreads to other locations in nearly 50% of cases, with the lungs being the most common site of metastasis. The cause of synovial sarcoma has not yet been determined, however, it has been linked to chromosome X and chromosome 18 abnormalities in tumour cells.
Global Synovial Sarcoma Treatment Market Dynamics
Drivers
- Rising incidence of synovial sarcoma
According to the American Cancer Society, the incidence of synovial sarcoma in the United States for 2018 is expected to be 13,040 patients, with 7,370 males and 5,670 females. Extensive research and development in this field for the development of novel therapies for the treatment of synovial sarcoma is expected to drive the growth of the global synovial sarcoma treatment market during the forecast period. For instance, Accuronix Therapeutics, Advenchen Laboratories, LLC, Immune Design, Cue Biopharma, and others, are conducting research and development of novel immunotherapy candidates for the treatment of synovial sarcoma.
- Technological advancements
The US Food and Drug Administration (FDA) designated Adaptimmune Therapeutics' NY-ESO-1 T-cell therapy as a T-Cell therapy breakthrough. Immunocore, a biotechnology company based in the United Kingdom, is developing ImmTAC (Immune mobilising monoclonal TCRs), which has potential applications in a variety of cancers, including synovial sarcoma. Furthermore, research on novel vaccines for the treatment of synovial sarcoma is underway, which could expand treatment options for the disease. During the forecast period, these factors are drive the growth of synovial sarcoma treatment market.
Opportunities
- Rising clinical trials
A robust and promising clinical pipeline is expected to fuel the synovial sarcoma treatment market in the near future. There are 83 pipeline therapeutics for synovial sarcoma treatment, with 8 drugs in clinical phase III. In addition, novel technologies such as ZVex and GLAAS technology, RESOLYSIN technology, and tumor-specific cytotoxic T-cell treatment are yielding promising results. Thus, a significant pipeline of drugs, growing public awareness, and increased funding for research are major factors driving market growth.
Restraints/Challenges
- High costs
The side effects associated with cancer treatment, high costs and uncertainty of the results of clinical trials are expected to affect the market's growth during the forecast period.
This synovial sarcoma treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the synovial sarcoma treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
- In Dec 2019, Adaptimmune Therapeutics plc announced that it has received the FDA Regenerative Medicine Advanced Therapy (RMAT) designation for ADP-A2M4 to treat synovial sarcoma.
Global Synovial Sarcoma Treatment Market Scope
The synovial sarcoma treatment market is segmented on the basis of diagnosis, type, treatment, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Diagnosis
- Imaging
- Biopsy
- Others
Type
- ACXT-3102
- AL-3818
- Axitinib
- CMB-305
- CUE-102
- Others
Treatment
- Surgery
- Anti-Angiogenesis
- Drugs Radiation Therapy
- Chemotherapy
End-Users
- Hospitals
- Specialty Clinics
- Oncology Centers
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Others
Synovial Sarcoma Treatment Market Regional Analysis/Insights
The synovial sarcoma treatment market is analyzed and market size insights and trends are provided by country, diagnosis, type, treatment, end-users and distribution channel as referenced above.
The countries covered in the synovial sarcoma treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the synovial sarcoma treatment market due to the presence of key manufacturers of the product is high and growing healthcare expenditure, research and development activities which contributes to raising the significant market growth.
Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 owing to improve the new research and developments on synovial sarcoma treatment market.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed base and New Technology Penetration
The synovial sarcoma treatment market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for synovial sarcoma treatment market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the synovial sarcoma treatment market. The data is available for historic period 2011-2021.
Competitive Landscape and Synovial Sarcoma Treatment Market Share Analysis
The synovial sarcoma treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to synovial sarcoma treatment market.
Some of the major players operating in the synovial sarcoma treatment market are:
- F. Hoffmann-La Roche Ltd (Switzerland)
- Bayer AG (Germany)
- Epizyme (U.S.)
- Cue Biopharma (U.S.)
- Eli Lilly and Company (U.S.)
- Adaptimmune Therapeutics Plc (U.K.)
- Advenchen Laboratories LLC (U.S.)
- EpiZyme Inc (U.S.)
- Merck & Co., Inc (U.S.)
- Immunocore Ltd (U.K.)
- Johnson & Johnson Private Limited (U.S.)
- Karyopharm Therapeutics Inc (U.S.)
- Novartis AG (Switzerland)
- Pfizer Inc. (U.S.)
- Takara Bio Inc (Japan)
SKU-